Cantor Fitzgerald analyst William Tanner believes TherapeuticsMD's loan agreement should remove the perception of a financing overhang. The financing is a "potentially important tool to blunt the investor malaise that often arises after positive events when capital raises are expected," Tanner tells investors in a post-earnings research note. He continues to believe TherapeuticsMD is well-positioned to bring two important new therapies to the market for treating conditions associated with menopause. The analyst lowered his price target for the shares to $26 from $28 and reiterates an Overweight rating on the name.